[go: up one dir, main page]

EA200101026A1 - Предварительно желатинированный крахмал в композиции с контролируемым высвобождением - Google Patents

Предварительно желатинированный крахмал в композиции с контролируемым высвобождением

Info

Publication number
EA200101026A1
EA200101026A1 EA200101026A EA200101026A EA200101026A1 EA 200101026 A1 EA200101026 A1 EA 200101026A1 EA 200101026 A EA200101026 A EA 200101026A EA 200101026 A EA200101026 A EA 200101026A EA 200101026 A1 EA200101026 A1 EA 200101026A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
hydrophilic
controlled release
gelatinized starch
preliminary
Prior art date
Application number
EA200101026A
Other languages
English (en)
Other versions
EA005291B1 (ru
Inventor
Роже Петрус Гереберн Вандекрюис
Эжен Мари Йозеф Янс
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200101026(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of EA200101026A1 publication Critical patent/EA200101026A1/ru
Publication of EA005291B1 publication Critical patent/EA005291B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Настоящее изобретение относится к использованию предварительно желатинированного крахмала для предупреждения демпинга дозы из гидрофильной композиции с контролируемым высвобождением. Оно также относится к гидрофильной композиции с контролируемым высвобождением, более конкретно, к гидрофильной матричной композиции с контролируемым высвобождением и к твердым дозированным формам, получаемым на ее основе, предпочтительно для однократного ежедневного перорального введения. Гидрофильная композиция с контролируемым высвобождением включает предварительно желатинированный крахмал, один или более активных ингредиентов, один или более вязких гидрофильных полимеров и необязательно дополнительные фармацевтически приемлемые средства, применяемые для составления композиции. Предпочтительные гидрофильные полимеры включают гидроксипропилцеллюлозу и гидроксипропилметилцеллюлозу.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200101026A 1999-03-31 2000-03-24 Применение предварительно желатинированного крахмала в композиции с контролируемым высвобождением EA005291B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99201018 1999-03-31
PCT/EP2000/002620 WO2000059477A1 (en) 1999-03-31 2000-03-24 Pregelatinized starch in a controlled release formulation

Publications (2)

Publication Number Publication Date
EA200101026A1 true EA200101026A1 (ru) 2002-06-27
EA005291B1 EA005291B1 (ru) 2004-12-30

Family

ID=8240051

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200401009A EA200401009A1 (ru) 1999-03-31 2000-03-24 Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
EA200101026A EA005291B1 (ru) 1999-03-31 2000-03-24 Применение предварительно желатинированного крахмала в композиции с контролируемым высвобождением

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200401009A EA200401009A1 (ru) 1999-03-31 2000-03-24 Предварительно желатинированный крахмал в композиции с контролируемым высвобождением

Country Status (27)

Country Link
US (3) US6667060B1 (ru)
EP (3) EP1611881A1 (ru)
JP (2) JP4928668B2 (ru)
KR (3) KR100660594B1 (ru)
CN (1) CN1208090C (ru)
AT (1) ATE313319T1 (ru)
AU (1) AU776645B2 (ru)
BG (3) BG65470B1 (ru)
BR (1) BR0009437A (ru)
CA (1) CA2371940C (ru)
CZ (2) CZ2006443A3 (ru)
DE (1) DE60024981T2 (ru)
DK (1) DK1169024T3 (ru)
EA (2) EA200401009A1 (ru)
EE (1) EE05022B1 (ru)
ES (2) ES2688273T3 (ru)
HK (1) HK1044715B (ru)
HR (1) HRP20010700B1 (ru)
HU (1) HU230440B1 (ru)
IL (3) IL145661A0 (ru)
MX (1) MX339071B (ru)
NO (2) NO332167B1 (ru)
NZ (1) NZ514890A (ru)
PL (1) PL198797B1 (ru)
SI (1) SI1169024T1 (ru)
SK (1) SK288541B6 (ru)
WO (1) WO2000059477A1 (ru)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200401009A1 (ru) * 1999-03-31 2004-12-30 Янссен Фармацевтика Н.В. Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
CA2428971A1 (en) * 2000-11-14 2003-05-01 New River Pharmaceuticals Inc. Conjugates of a therapeutic agent and a peptide carrier
US20110092677A1 (en) * 2001-08-30 2011-04-21 Biorexis Technology, Inc. Modified transferin-antibody fusion proteins
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8663687B2 (en) * 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US20060039958A1 (en) * 2003-05-28 2006-02-23 Monosolrx, Llc. Multi-layer films having uniform content
US7425292B2 (en) * 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US7357891B2 (en) * 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
NZ532589A (en) * 2001-11-07 2005-02-25 Synthon Bv Tamsulosin tablets
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US20050158380A1 (en) * 2002-06-07 2005-07-21 Manish Chawla Sustained release oral dosage forms of gabapentin
AR040683A1 (es) * 2002-07-25 2005-04-13 Pharmacia Corp Composicion de tabletas de liberacion sostenida que comprende un agonista de los receptores de la dopamina
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
MY142204A (en) 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
US8637512B2 (en) * 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
AU2007254665B2 (en) * 2002-07-29 2010-08-19 Alza Corporation Methods and dosage forms for controlled delivery and paliperidone
ATE373472T1 (de) * 2002-07-29 2007-10-15 Alza Corp Verfahren und dosierformen für die kontrollierte abgabe von paliperidon
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
PL376476A1 (en) * 2002-10-24 2005-12-27 Merz Pharma Gmbh & Co.Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
AU2003288588A1 (en) * 2002-12-16 2004-07-09 Ranbaxy Laboratories Limited An extended release pharmaceutical composition of phenytoin sodium
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060105036A1 (en) * 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
CA2529746C (en) * 2003-06-16 2010-08-03 Andrx Pharmaceuticals, Llc Oral extended-release composition
EP1645568A4 (en) 2003-07-11 2007-06-27 Asahi Kasei Chemicals Corp FUNCTIONAL STARCH POWDER
TWI366442B (en) * 2003-07-30 2012-06-21 Novartis Ag Palatable ductile chewable veterinary composition
ATE551339T1 (de) 2003-11-05 2012-04-15 Sarcode Bioscience Inc Modulatoren der zellulären adhäsion
ATE403418T1 (de) * 2004-03-10 2008-08-15 Ranbaxy Lab Ltd Verfahren zur herstellung von festen dosierformen von amorphem valganciclovir-hydrochlorid
WO2005067887A2 (en) * 2004-03-24 2005-07-28 Actavis Group Formulations of ramipril
US20050233010A1 (en) * 2004-04-19 2005-10-20 Satow Philip M Lithium combinations, and uses related thereto
EP1591107A1 (en) * 2004-04-28 2005-11-02 Pfizer GmbH Arzneimittelwerk Gödecke Process for the selective increase of a release rate of an active material from a pharmaceutical composition
MXPA06012505A (es) 2004-04-30 2006-12-15 Warner Lambert Co Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central.
TWI338583B (en) 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation
EA200700388A1 (ru) * 2004-08-13 2007-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
JP4757872B2 (ja) 2004-08-13 2011-08-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその医薬品として許容される塩を含む放出が延長された錠剤調合物、その製造方法及びその使用
EP1803447B1 (en) * 2004-09-09 2009-07-22 Psicofarma, S.A. De C.V. Pharmaceutical composition for the sustained release of hydralazine and use thereof as a support for cancer treatment
ZA200704768B (en) * 2004-11-05 2008-08-27 King Pharmaceuticals Res & Dev Stabilized ramipril compositions and methods of making
US20060105992A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
WO2006052921A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Cyclodextrin solubilizers for liquid and semi-solid formulations
US20060121108A1 (en) * 2004-12-02 2006-06-08 Prasad C K System and method for producing a directly compressible, high-potency formulation of metformin hydrochloride
EP1830886B1 (en) 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
JP5739080B2 (ja) * 2005-01-27 2015-06-24 アレムビック・リミテッドＡｌｅｍｂｉｃ Ｌｉｍｉｔｅｄ レベチラセタムの徐放性製剤
CN101166543B (zh) * 2005-04-28 2014-07-16 卫材R&D管理有限公司 含抗痴呆药物的组合物
HUE031979T2 (en) 2005-05-17 2017-08-28 Sarcode Bioscience Inc Preparations and methods for treating eye disorders
KR101552033B1 (ko) * 2005-05-26 2015-09-09 다이닛본 스미토모 세이야꾸 가부시끼가이샤 약학 조성물
US8252776B2 (en) * 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
DE102005033943A1 (de) * 2005-07-20 2007-02-22 Hexal Ag Nicht-ausspuckbarer, oraler, schnell-zerfallender Film für ein Neuroleptikum
WO2007018190A1 (ja) * 2005-08-10 2007-02-15 Shionogi & Co., Ltd. 苦味抑制製剤
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
US7803413B2 (en) * 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
DE102006003512A1 (de) * 2006-01-24 2007-08-02 Bayer Schering Pharma Ag Plättchenförmige Arzneimittel zur transbukkalen Applikation von Arzneistoffen
WO2007090881A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Modified release formulation
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
US20070264346A1 (en) * 2006-02-16 2007-11-15 Flamel Technologies Multimicroparticulate pharmaceutical forms for oral administration
AU2007311591B2 (en) 2006-10-18 2010-10-07 Pfizer Products Inc. Biaryl ether urea compounds
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
EP2154995B1 (en) * 2007-05-23 2011-06-22 Firmenich S.A. Flavouring composition
US20080292683A1 (en) * 2007-05-24 2008-11-27 Monosolrx, Llc. Film shreds and delivery system incorporating same
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
EP2155169B1 (en) * 2007-06-08 2016-03-23 Boehringer Ingelheim International GmbH Extended release formulation of nevirapine
KR20100020459A (ko) * 2007-06-08 2010-02-22 아드레넥스 파마슈티컬스, 아이엔씨. 지연 방출형 제제 및 아드레날린 조절부전의 치료방법
US9078824B2 (en) 2007-09-24 2015-07-14 The Procter & Gamble Company Composition and method of stabilized sensitive ingredient
US20090081294A1 (en) * 2007-09-26 2009-03-26 Gin Jerry B Sustained release dosage form for lubricating an oral cavity
US20090081291A1 (en) * 2007-09-26 2009-03-26 Gin Jerry B Sustained Release Dosage Forms For Delivery of Agents to an Oral Cavity of a User
EP2203166B1 (en) * 2007-10-16 2015-05-06 Paladin Labs Inc. Bilayer composition for the sustained release of acetaminophen and tramadol
MX2010004281A (es) 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
US8298583B2 (en) 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
CA2707980C (en) 2007-12-17 2015-05-12 Labopharm Inc. Misuse preventative, controlled release formulation
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
CN102105136B (zh) 2008-03-11 2014-11-26 蒂宝制药公司 包含非-阿片类止痛剂和阿片类止痛剂的组合的胃滞留型缓释剂型
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
WO2009128932A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Delivery of lfa-1 antagonists to the gastrointestinal system
WO2009139817A2 (en) * 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
AU2013205004B2 (en) * 2008-06-30 2015-08-27 Tocagen Inc. Formulations of 5-fluorocytosine and Uses Thereof
JP6092514B2 (ja) 2008-06-30 2017-03-08 トカジェン インコーポレーテッド ５−フルオロシトシン製剤およびその使用
NZ590852A (en) * 2008-07-16 2013-03-28 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands trans-1{ 4-[2-[4-(2,3-dichlorophenyl)-piperizin-1-yl]-ethyl]-cyclohexyl} -3,3-dimethyl-urea also known as cariprazine
WO2010011712A1 (en) * 2008-07-22 2010-01-28 General Mills, Inc. Fruit products containing omega-3 fatty acids
WO2010017310A1 (en) 2008-08-06 2010-02-11 Medicis Pharmaceutical Corporation Method for the treatment of acne and certain dosage forms thereof
US20100040727A1 (en) * 2008-08-18 2010-02-18 Monosol Rx, Llc Method for Improving Uniformity of Content in Edible Film Manufacturing
WO2010055002A1 (en) * 2008-11-17 2010-05-20 Basf Se Starch-containing granular formulation
US8282954B2 (en) * 2008-12-15 2012-10-09 Monosol Rx, Llc Method for manufacturing edible film
AU2009327312A1 (en) 2008-12-16 2011-08-04 Labopharm Europe Limited Misuse preventative, controlled release formulation
GEP20146013B (en) 2009-01-23 2014-01-27 Aziende Chimiche Riunite Angelini Francesco A C R A F S P A It Controlled release pharmaceutical or food formulation and method of preparation thereof
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
US20100285130A1 (en) * 2009-05-06 2010-11-11 Monosol Rx, Llc Coating of complexed actives in film formulations
US20100297232A1 (en) * 2009-05-19 2010-11-25 Monosol Rx, Llc Ondansetron film compositions
SG177536A1 (en) 2009-07-09 2012-03-29 Oshadi Drug Administration Ltd Matrix carrier compositions, methods and uses
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CN102753196A (zh) * 2009-12-10 2012-10-24 莫诺索尔克斯有限公司 口服薄膜条内掩味的pH敏感性化合物
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
WO2011090694A1 (en) * 2009-12-28 2011-07-28 Monosol Rx, Llc Orally administrable film dosage forms containing ondansetron
NZ629036A (en) * 2010-02-24 2014-09-26 Zoetis Llc Veterinary compositions
US8975387B1 (en) 2010-03-22 2015-03-10 North Carolina State University Modified carbohydrate-chitosan compounds, methods of making the same and methods of using the same
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
BR112013015645A2 (pt) * 2010-12-21 2016-08-09 Akzo Nobel Chemicals Int Bv composição para cuidados pessoais
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
JP5960523B2 (ja) * 2012-06-29 2016-08-02 旭化成株式会社 加工澱粉と溶出制御剤からなる固形製剤
KR102157608B1 (ko) 2012-07-25 2020-09-18 에스에이알코드 바이오사이언스 인코포레이티드 Lfa-1 저해제 및 그의 다형체
JP6252475B2 (ja) * 2012-07-27 2017-12-27 大正製薬株式会社 外用剤組成物
CA2902348C (en) 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
CN106061494A (zh) 2013-10-10 2016-10-26 辛纳吉制药公司 可用于治疗阿片样物质诱导的功能障碍的鸟苷酸环化酶的激动剂
US9561187B1 (en) * 2014-02-03 2017-02-07 CMAX Technologies, Inc. Sustained release metoprolol formulations
CN106715443A (zh) * 2014-03-26 2017-05-24 坎格特生物技术制药有限责任公司 Fl118母核化学结构平台产生用于治疗人类疾病的fl118衍生物的用途
CN103948550A (zh) * 2014-04-22 2014-07-30 青岛市市立医院 一种西沙必利分散片及其制备方法
BR112016028045A8 (pt) 2014-06-02 2021-05-04 Anavo Tech Llc biopolímeros modificados, e seus métodos de produção
BE1021194B1 (nl) * 2014-07-07 2015-07-14 Nordic Specialty Pharma Bvba Paracetamol tabletten
CA3004346A1 (en) 2015-11-23 2017-06-01 Tethis, Inc. Coated particles and methods of making and using the same
EP3402804A1 (en) 2016-01-11 2018-11-21 Synergy Pharmaceuticals Inc. Formulations and methods for treating ulcerative colitis
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN109310646A (zh) 2016-05-05 2019-02-05 阿奎斯蒂弗医疗股份有限公司 增强递送的肾上腺素组合物
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
CN107198680A (zh) * 2016-10-12 2017-09-26 钟术光 缓释制剂
JP7426685B2 (ja) * 2018-06-14 2024-02-02 株式会社東洋新薬 錠剤
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
GB2606585B (en) * 2021-03-31 2024-02-14 Tate & Lyle Solutions Usa Llc Pregelatinized inhibited hollow starch products and methods of making and using them

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
JPS615027A (ja) * 1984-06-18 1986-01-10 Sadahiro Nakano 徐放性固形製剤
GB8624213D0 (en) 1986-10-09 1986-11-12 Sandoz Canada Inc Sustained release pharmaceutical compositions
FR2610827B1 (fr) * 1987-02-18 1991-09-13 Pf Medicament Comprime de dihydroergotamine (d.h.e.) du type a matrice hydrophile et son procede de fabrication
US4806359A (en) * 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
FR2618073B1 (fr) * 1987-07-16 1990-09-07 Pf Medicament Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
FR2666506A1 (fr) 1990-09-07 1992-03-13 Pf Medicament Comprime a liberation prolongee a base de 5-mononitrate d'isosorbide et son procede de preparation.
US5534496A (en) * 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
HUT72975A (en) * 1993-02-26 1996-06-28 Procter & Gamble Bisacodyl dosage form
US5698226A (en) 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
US5635208A (en) * 1993-07-20 1997-06-03 Mcneil-Ppc, Inc. Granulation process for producing an acetaminophen and diphenhydramine hydrochloride composition and composition produced by same
TW349870B (en) 1993-09-30 1999-01-11 Janssen Pharmaceutica Nv An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof
JPH07204796A (ja) * 1994-01-14 1995-08-08 Kawasaki Steel Corp 金属薄帯の製造装置
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
ZA959221B (en) 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release
ES2279519T3 (es) * 1995-05-02 2007-08-16 Taisho Pharmaceutical Co. Ltd Composicion para administracion por via oral.
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
JPH0952832A (ja) * 1995-08-10 1997-02-25 Takeda Chem Ind Ltd 医薬組成物
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
NZ325844A (en) * 1995-12-27 1999-06-29 Janssen Pharmaceutica Nv A bioadhesive tablet comprising a c16-c22alkyl fumarate as lubricant
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
DE59907885D1 (de) * 1998-09-26 2004-01-08 Aventis Pharma Gmbh Verfahren zur drucklosen herstellung von alpha, alpha-dimethylphenylessigsäure aus alpha, alpha-dimethylbenzylcyanid
EA200401009A1 (ru) * 1999-03-31 2004-12-30 Янссен Фармацевтика Н.В. Предварительно желатинированный крахмал в композиции с контролируемым высвобождением

Also Published As

Publication number Publication date
HUP0200611A3 (en) 2003-04-28
EP1649851A2 (en) 2006-04-26
NO20014724D0 (no) 2001-09-28
MXPA01009877A (es) 2002-05-06
CA2371940C (en) 2008-07-15
US8591945B2 (en) 2013-11-26
HU230440B1 (hu) 2016-06-28
CZ300551B6 (cs) 2009-06-17
EP1649851B1 (en) 2018-06-20
JP4928668B2 (ja) 2012-05-09
AU776645B2 (en) 2004-09-16
DE60024981D1 (de) 2006-01-26
IL145661A (en) 2013-10-31
KR100660594B1 (ko) 2006-12-22
US20090191266A1 (en) 2009-07-30
EP1611881A1 (en) 2006-01-04
BR0009437A (pt) 2002-01-15
KR20020002384A (ko) 2002-01-09
NO20014724L (no) 2001-09-28
IL145661A0 (en) 2002-06-30
CN1345233A (zh) 2002-04-17
US20040062805A1 (en) 2004-04-01
US6667060B1 (en) 2003-12-23
MX339071B (es) 2016-05-09
WO2000059477A1 (en) 2000-10-12
JP2011006485A (ja) 2011-01-13
CZ20013375A3 (cs) 2002-05-15
CA2371940A1 (en) 2000-10-12
BG65470B1 (bg) 2008-09-30
EE05022B1 (et) 2008-06-16
NZ514890A (en) 2003-05-30
CZ307700B6 (cs) 2019-02-20
EP1649851A3 (en) 2008-04-23
EP1169024B1 (en) 2005-12-21
HK1044715B (zh) 2006-02-17
SI1169024T1 (sl) 2006-06-30
NO332167B1 (no) 2012-07-09
PL355096A1 (en) 2004-03-22
PL198797B1 (pl) 2008-07-31
ES2255490T3 (es) 2006-07-01
HUP0200611A2 (hu) 2002-07-29
AU3963800A (en) 2000-10-23
EP1169024A1 (en) 2002-01-09
HRP20010700B1 (hr) 2011-01-31
NO342239B1 (no) 2018-04-23
DE60024981T2 (de) 2006-09-14
SK13542001A3 (sk) 2002-08-06
CN1208090C (zh) 2005-06-29
HK1044715A1 (en) 2002-11-01
EA005291B1 (ru) 2004-12-30
IL219820A0 (en) 2012-06-28
EA200401009A1 (ru) 2004-12-30
KR20060097068A (ko) 2006-09-13
HRP20010700A2 (en) 2003-04-30
SK288541B6 (sk) 2018-03-05
ES2688273T3 (es) 2018-10-31
BG66095B1 (bg) 2011-04-29
BG105857A (en) 2002-04-30
BG110060A (bg) 2008-12-30
KR20100036398A (ko) 2010-04-07
DK1169024T3 (da) 2006-05-08
EE200100505A (et) 2002-12-16
ATE313319T1 (de) 2006-01-15
NO20111249L (no) 2001-09-28
JP2002541090A (ja) 2002-12-03
CZ2006443A3 (cs) 2019-02-20

Similar Documents

Publication Publication Date Title
EA200101026A1 (ru) Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
AU1079701A (en) Oral transmucosal drug dosage using solid solution
EP0966966A3 (en) Nefazodone dosage form
BR0014383A (pt) Composições de liberação controlada compreendendo nimesulida
AR026916A1 (es) Combinaciones farmaceuticas y su uso en el tratamiento de desordenes gastrointestinales
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
EP1365749A4 (en) PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS FOR USE WITH WEICHGELATINE FORMULATIONS
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
SE9301877D0 (sv) In situ gel for therapeutic use
ATE374600T1 (de) Pharmazeutische formulierung enthaltend olanzapin
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
MXPA02006034A (es) Formas de dosis mucosaloral de apomorfina.
EA200701091A1 (ru) Противозачаточный фармацевтический препарат
EA200101157A1 (ru) 14β-H-СТЕРОЛЫ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ПРИМЕНЕНИЕ ЭТИХ ПРОИЗВОДНЫХ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ, РЕГУЛИРУЮЩИХ МЕЙОЗ
MY145885A (en) Controlled release formulations for oral administration
DE50311479D1 (de) Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung

Legal Events

Date Code Title Description
MK4A Patent expired

Designated state(s): AM AZ BY KZ KG MD TJ TM RU